EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference

Soichiro Ide, Noriaki Iwase, Kenichi Arai, Masahiro Kojima, Shigeru Ushiyama, Kaori Taniko, Kazutaka Ikeda iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Soichiro Ide und 6 weiteren Autor:innen. Beteiligte Einrichtung: Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan. Hauptthemen laut MEDLINE: Narcotic Antagonists, Opioid-Related Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, UBE Corporation, JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although opioids are widely used to treat moderate to severe pain, opioid addiction and the opioid overdose epidemic are becoming more serious. Although opioid receptor antagonists/partial agonists, such as naltrexone and buprenorphine, have relatively low selectivity for the μ-opioid receptor (MOP), they have been used for the management of opioid use disorder. The utility of highly selective MOP antagonists remains to be evaluated. Here, we biologically and pharmacologically evaluated a novel nonpeptide ligand, UD-030, as a selective MOP antagonist. UD-030 had more than 100-fold higher binding affinity for the human MOP (Ki = 3.1 nM) than for δ-opioid, κ-opioid, and nociceptin receptors (Ki = 1800, 460, and 1800 nM, respectively) in competitive binding assays. The [35S]-GTPγS binding assay showed that UD-030 acts as a selective MOP full antagonist. The oral administration of UD-030 dose-dependently suppressed the acquisition and expression of morphine-induced conditioned place preference in C57BL/6J mice, and its effects were comparable to naltrexone. These results indicate the UD-030 may be a new candidate for the treatment of opioid use disorder, with characteristics that differ from traditional medications that are in clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Narcotic AntagonistsOpioid-Related DisordersMiceHumansAnimalsMorphineNaltrexoneAnalgesics, OpioidReceptors, Opioid, deltaMice, Inbred C57BLReceptors, Opioid, mu

Stichwörter der Autor:innen

CPPaddictionmorphinenaltrexoneopioid receptor antagonistreward

Substanzen

Narcotic AntagonistsMorphineNaltrexoneAnalgesics, OpioidReceptors, Opioid, deltaReceptors, Opioid, mu

Autor:innen und Institutionen

  • Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
  • UBE Corporation, Yamaguchi 755-8633, Japan.
  • Sanwa Kagaku Kenkyusho Co., Ltd., Aichi 461-8631, Japan.

ORCID-Profile: Kazutaka Ikeda

Förderung

  • Japan Society for the Promotion of Science
  • UBE Corporation
  • JSPS

Zitieren

APA

Ide, S., Iwase, N., Arai, K., Kojima, M., Ushiyama, S., Taniko, K., & Ikeda, K. (2023). Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043351

Vancouver

Ide S, Iwase N, Arai K, Kojima M, Ushiyama S, Taniko K, et al. Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043351

BibTeX
@article{Ide2023,
  author = {Ide, Soichiro and Iwase, Noriaki and Arai, Kenichi and Kojima, Masahiro and Ushiyama, Shigeru and Taniko, Kaori and Ikeda, Kazutaka},
  title = {Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043351}
}
Kostenlos starten →